

Press Release September 20, 2018

Chaperone Therapeutics Awarded National Institutes of Health funding to develop therapeutics to slow the progression of Alzheimer's disease

Chaperone Therapeutics, Inc. is pleased to announce receipt of funding from the National Institutes of Health National Institute on Aging. This funding will support Chaperone's preclinical development of proprietary lead molecules to deliver a clinical candidate as a disease-modifying therapy to ameliorate the symptoms of Alzheimer's disease. Chaperone Therapeutics' approach exploits the activation of a central neuronal stress protection pathway that is deficient in Alzheimer's disease brain to attenuate the neuronal dysfunction, protein misfolding and chronic inflammation associated with Alzheimer's disease.